IDEAYA Biosciences Inc IDYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
Trading Information
- Previous Close Price
- $30.36
- Day Range
- $26.68–31.85
- 52-Week Range
- $26.68–42.68
- Bid/Ask
- $25.42 / $27.98
- Shares Outstanding
- 96.69M
- Market Cap
- $2.65B
- Volume/Avg
- 2M / 895,428
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 77.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 145
- Website
- https://www.ideayabio.com
Valuation
Metric | IDYA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.69 |
Price/Sales | 77.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IDYA |
|---|---|
Quick Ratio | 8.80 |
Current Ratio | 9.04 |
Interest Coverage | — |
Quick Ratio
IDYA
Profitability
Metric | IDYA |
|---|---|
Return on Assets (Normalized) | −30.71% |
Return on Equity (Normalized) | −33.62% |
Return on Invested Capital (Normalized) | −36.67% |
Return on Assets
IDYA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|vmKj^F | LOCK|T<!Fw | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|vxr^Pw | LOCK|%mKJX | $99B | |||
| Moderna Inc MRNA | LOCK|#&^QXs! | LOCK|#q | $87B | |||
| argenx SE ADR ARGX | LOCK|%JTYR<@ | LOCK|W@% | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|bm#vq? | LOCK|<>< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|$%^^%mR | LOCK|By>p | $31B | |||
| Incyte Corp INCY | LOCK|ht!%@m | LOCK|lR | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#CNGM^ | LOCK|v#<CY | $21B | |||
| BioNTech SE ADR BNTX | LOCK|ZPb>d$ | LOCK|gFr | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|^@h$zZ | LOCK|#! | $15B |